AtriCure, Inc. 10-Q Summary: Period Ended September 30, 2005
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2005, for AtriCure, Inc., a Delaware corporation developing and selling surgical devices for the treatment of atrial fibrillation (AF). The Company's primary product is the AtriCure bipolar ablation system. During the quarter, the Company consummated its Initial Public Offering (IPO) on August 10, 2005, and simultaneously acquired Enable Medical Corporation, the manufacturer of its disposable handpieces.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2005 | Nine Months Ended Sept 30, 2005 |
|---|---|---|
| Revenues | $7.17 million | $22.40 million |
| Gross Profit | $5.15 million (72% margin) | $16.48 million (74% margin) |
| Net Loss (Available to Common) | $(3.96) million | $(8.67) million |
| Loss Per Share (Basic/Diluted) | $(0.49) | $(2.18) |
| Cash and Cash Equivalents | $38.34 million (as of Sept 30, 2005) | N/A |
| Working Capital | $39.64 million | N/A |
| Total Debt (Current + Long-term) | $1.53 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 59% year-over-year for the three months ended September 30, 2005, and 67% for the nine-month period. Growth was driven by increased unit volume domestically and internationally and the introduction of the bipolar pen.
- Operating Expenses: Total operating expenses rose significantly due to headcount expansion (sales and R&D), increased educational grants, and the integration of Enable Medical Corporation. SG&A expenses increased 63% for the quarter and 67% for the nine-month period.
- Liquidity Transformation: Cash and cash equivalents surged from $5.18 million at December 31, 2004, to $38.34 million at September 30, 2005. This increase was primarily due to net proceeds of approximately $43.2 million from the August 2005 IPO.
- Preferred Stock Conversion: All outstanding Series A and Series B preferred stock was converted to common stock upon the closing of the IPO, eliminating future preferred stock interest expense.
- Acquisition Impact: The acquisition of Enable Medical Corporation for approximately $6.4 million (net of cash acquired) added $3.8 million in goodwill and proprietary manufacturing technology to the balance sheet.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects operating expenses to continue to increase in absolute terms and as a percentage of revenue to support sales growth, R&D, and regulatory efforts. The Company believes its current cash position is sufficient to meet capital needs for at least the next 12 months. The Company is conducting the RESTORE-SR clinical trial to support FDA approval for the treatment of AF during open-heart surgery and has obtained approval for a feasibility study for sole-therapy minimally invasive treatment.
Key Risks and Contingencies:
- Regulatory Status: The Company's primary product is currently used "off-label" for the treatment of AF. The FDA denied a 510(k) clearance in June 2005, requiring the Company to pursue a more rigorous and costly Pre-Market Approval (PMA) process. The Company cannot legally market the system for AF treatment until approval is granted.
- Market Acceptance: Future growth depends on the development of the sole-therapy minimally invasive AF treatment market and the willingness of doctors to change referral practices.
- Competition: The Company faces competition from larger medical device companies (e.g., Medtronic, Guidant) with broader product offerings and greater resources.
- Supply Chain: The Company relies on single-source suppliers for critical components, including the ablation sensing unit (ASU), though the acquisition of Enable mitigates some supply risks for handpieces.
- Legal Proceedings: A competitor filed a suit in August 2005 regarding the hiring of a former employee; management does not currently expect a material adverse effect.
Investor Verification Checklist
- FDA PMA Timeline: Verify the status and projected timeline for the Pre-Market Approval (PMA) application required for the cardiac indication, given the denial of the 510(k) clearance.
- Clinical Trial Enrollment: Confirm enrollment rates for the RESTORE-SR trial, which was reported as slower than expected (approx. 15.9% of treatment patients enrolled as of Sept 30, 2005).
- Off-Label Promotion Compliance: Assess the Company's compliance with FDA regulations regarding off-label promotion and the risk of enforcement actions.
- Acquisition Integration: Review the integration progress of Enable Medical Corporation and the realization of expected margin improvements.
- Reimbursement Policies: Monitor changes in Medicare and private payor reimbursement policies for surgical AF treatments, which directly impact market adoption.